



HAL
open science

Theranostics of Primary Prostate Cancer: Beyond PSMA and GRP-R

Romain Schollhammer, Marie-Laure Quintyn Ranty, Henri de Clermont Gallerande, Florine Cavelier, Ibai E Valverde, Delphine Vimont, Elif Hindié, Clément Morgat

► **To cite this version:**

Romain Schollhammer, Marie-Laure Quintyn Ranty, Henri de Clermont Gallerande, Florine Cavelier, Ibai E Valverde, et al.. Theranostics of Primary Prostate Cancer: Beyond PSMA and GRP-R. *Cancers*, 2023, 15 (8), pp.2345. 10.3390/cancers15082345 . hal-04075693

HAL Id: hal-04075693

<https://hal.science/hal-04075693>




Submitted on 20 Apr 2023

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

Article

Theranostics of Primary Prostate Cancer: Beyond PSMA and GRP-R

Romain Schollhammer^{1,2}, Marie-Laure Quintyn Ranty³, Henri de Clermont Gallerande^{1,2}, Florine Cavelier⁴ , Ibai E. Valverde⁵ , Delphine Vimont², Elif Hindié^{1,2,6} and Clément Morgat^{1,2,*} 

¹ Nuclear Medicine Department, Bordeaux University Hospital, 33000 Bordeaux, France

² INCIA, University of Bordeaux, CNRS, EPHE, UMR 5287, 33000 Bordeaux, France

³ Department of Pathology, University Hospital of Toulouse, 31000 Toulouse, France

⁴ Institut des Biomolécules Max Mousseron IBMM, UMR 5247, CNRS, Université Montpellier, ENSCM, Pôle Chimie Balard, 1919 Route de Mende, Cedex 5, 34293 Montpellier, France

⁵ Institut de Chimie Moléculaire de l'Université de Bourgogne, UMR 6302, CNRS, Université Bourgogne Franche-Comté, 9 Avenue Alain Savary, 21000 Dijon, France

⁶ Institut Universitaire de France (IUF), 75231 Paris, France

* Correspondence: clement.morgat@u-bordeaux.fr

Simple Summary: The accurate assessment of the aggressiveness and localization of primary prostate cancer lesions are essential for treatment decision making. Around 15% of lesions are missed by PSMA Positron-Emission tomography/computed Tomography (PET/CT). The aim of our study was to investigate the potential of novel surface markers to detect PSMA-negative lesions using immunohistochemistry and autoradiography techniques. Our work demonstrates that targeting both PSMA and neurotensin receptors might detect all intra-prostatic lesions. This new finding has implications for the future theranostics of primary prostate cancer.

Abstract: The imaging of Prostate-Specific Membrane Antigen (PSMA) is now widely used at the initial staging of prostate cancers in patients with a high metastatic risk. However, its ability to detect low-grade tumor lesions is not optimal. **Methods:** First, we prospectively performed neurotensin receptor-1 (NTS₁) IHC in a series of patients receiving both [⁶⁸Ga]Ga-PSMA-617 and [⁶⁸Ga]Ga-RM2 before prostatectomy. In this series, PSMA and GRP-R IHC were also available (n = 16). Next, we aimed at confirming the PSMA/GRP-R/NTS₁ expression profile by retrospective autoradiography (n = 46) using a specific radiopharmaceuticals study and also aimed to decipher the expression of less-investigated targets such as NTS₂, SST₂ and CXCR4. **Results:** In the IHC study, all samples with negative PSMA staining (two patients with ISUP 2 and one with ISUP 3) were strongly positive for NTS₁ staining. No samples were negative for all three stains—for PSMA, GRP-R or NTS₁. In the autoradiography study, binding of [¹¹¹In]In-PSMA-617 was high in all ISUP groups. However, some samples did not bind or bound weakly to [¹¹¹In]In-PSMA-617 (9%). In these cases, binding of [¹¹¹n]In-JMV 6659 and [¹¹¹In]In-JMV 7488 towards NTS₁ and NTS₂ was high. **Conclusions:** Targeting PSMA and NTS₁/NTS₂ could allow for the detection of all intraprostatic lesions.

Keywords: prostate cancer; neuropeptide; PSMA; GRP-R; NTS₁; NTS₂; neurotensin



Citation: Schollhammer, R.; Quintyn Ranty, M.-L.; de Clermont Gallerande, H.; Cavelier, F.; Valverde, I.E.; Vimont, D.; Hindié, E.; Morgat, C. Theranostics of Primary Prostate Cancer: Beyond PSMA and GRP-R. *Cancers* **2023**, *15*, 2345. <https://doi.org/10.3390/cancers15082345>

Academic Editor: David Wong

Received: 17 February 2023

Revised: 7 April 2023

Accepted: 13 April 2023

Published: 18 April 2023



Copyright: © 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<https://creativecommons.org/licenses/by/4.0/>).

1. Introduction

Prostate cancer is the most common cancer in men and the third leading cause of cancer death [1]. Prostate tumors are typically multifocal, composed of a combination of cells at different stages of differentiation; the histo-prognostic grade (ISUP score) obtained from biopsy samples then guides the management. However, prostate biopsies only provide a limited representation of the intraprostatic tumoral process. Indeed, the ISUP score is frequently modified after analysis of prostatectomy specimens. In addition, it is not uncommon for biopsies to be negative, despite a strong suspicion of prostate cancer. Several

studies have shown that performing multiparametric magnetic resonance imaging (mpMRI) before a series of biopsies increases the detection of lesions [2–4], but no imaging method is currently able to accurately estimate the histo-prognostic grade and their sensitivity is not optimal.

Focal therapies using focused ultrasound (HIFU—High Intensity Focused Ultrasound) or stereotactic radiotherapy are becoming increasingly important in the management of low-grade localized prostate cancers, mainly because of their low rates of complications. The accurate localization and characterization of the tumor lesion is therefore essential. Indeed, in many cases, no target is identified on mpMRI—thus preventing the use of these treatments. High-performance molecular imaging would guide these focal therapies.

The development of novel radiopharmaceuticals supports innovations in molecular imaging by improving sensitivity and specificity in the diagnosis and characterization of primary prostate tumors. For example, [⁶⁸Ga]Ga-PSMA (Prostate Specific Membrane Antigen) PET/CT (Positron Emission Tomography/Computed Tomography) is now widely used at the initial staging of prostate cancers in patients with high metastatic risk and in the context of biochemical recurrence [5,6]. However, its ability to detect low-grade tumor lesions is not optimal. Novel radiopharmaceuticals with a role in this setting would be helpful.

Tissue micro-imaging is a technique that allows for the pre-clinical evaluation of radiopharmaceuticals [7,8]. We recently compared the targeting of PSMA and GRP-R (Gastrin Releasing Peptide Receptor), by means of [¹¹¹In]In-PSMA-617 and [¹¹¹In]In-RM2, respectively. We showed good detection of low-grade tumor lesions by [¹¹¹In]In-RM2, superior to that of [¹¹¹In]In-PSMA [8]. Next, we translated these results into a Phase II study using [⁶⁸Ga]Ga-PSMA-617 PET/CT and [⁶⁸Ga]Ga-RM2 PET/CT. Again, we demonstrated a better detection of low-grade lesions by targeting GRP-R using [⁶⁸Ga]Ga-RM2 [9]. However, 15.6% of the lesions remained undetectable by both modalities.

New targets for prostate cancer are currently being studied, such as neurotensin receptor-1 (NTS₁) [10], somatostatin receptor-2 (SST₂) [11] or chemokine receptor-4 (CXCR4) [12]—suggested to be expressed in prostate cancer in a few small pilot studies. However, comparisons are needed.

Thus, the main objective of this study was to evaluate alternative targets for the better identification of intraprostatic lesions. Our strategy was based on a sequential approach: First, we prospectively performed NTS₁ IHC in a series of patients receiving both [⁶⁸Ga]Ga-PSMA-617 and [⁶⁸Ga]Ga-RM2 before prostatectomy. In this series, PSMA and GRP-R IHC were also available [9]. Next, we aimed at confirming the PSMA/GRP-R/NTS₁ expression profile by a retrospective autoradiography study and also aimed to decipher the expression of less-investigated targets such as NTS₂, SST₂ and CXCR4.

2. Materials and Methods

2.1. Patient Characteristics

Study 1: Formalin-fixed paraffin-embedded samples were prospectively available from patients enrolled in the NCT03604757 study, comparing [⁶⁸Ga]Ga-PSMA-617 PET/CT to [⁶⁸Ga]Ga-RM2 PET/CT in patients with localized prostate cancer that were candidates for radical prostatectomy. PSMA and GRP-R staining were performed during this study [9]. For the current study, 16 samples were available for additional NTS₁ staining and comparison with GRP-R and PSMA staining (six samples were considered as non-contributors).

Study 2: Forty-six frozen samples of prostate cancer were available from the Department of Pathology of the University Hospital of Toulouse, France. Patient samples were obtained after informed consent in accordance with the Declaration of Helsinki and stored at the “CRB Cancer des Hôpitaux de Toulouse (BB-0033-00014)” collection. According to French law, the CRB Cancer collection was declared to the Ministry of Higher Education and Research (DC- 2008-463) and a transfer agreement was obtained (AC-2013-1955) after approval by ethical committees (Conseil Scientifique du Centre de Ressources Biologiques). Clinical and biological annotations of the samples were declared to the CNIL (Comité

National Informatique et Libertés). None of these patients received hormone therapy or other systemic therapy prior to surgery. For each case, thirteen adjacent sections were used: one for hematoxylin-eosin-saffron (HES) staining and twelve for high-resolution microimaging (one section per radiopharmaceutical for total binding and another adjacent section for non-specific binding). An experienced pathologist manually drew tumoral areas on the HES-stained section. All patients were characterized according to their clinical and biochemical criteria including age, tumoral size (clinical and pathological sizes), PSA value and ISUP score.

2.2. NTS₁—Immunohistochemistry

Immunohistochemical assessments were performed as previously described [10]. Immunohistochemistry results were expressed as an immunoreactive score (IRS) that considered staining intensity and the percentage of stained tumor cells [13]. The final IRS score (the product of the staining intensity score and the percentage of positive cells score) thus ranged from 0 to 12: IRS 0–1 means no clear expression; IRS 2–3 indicates weak expression; IRS 4–8 indicates moderate expression; IRS 9–12 indicates strong expression. In order to study associations with other parameters, IHC results were dichotomized into two groups: low expression (regrouping absent/weak expression) and high expression (regrouping moderate/strong expression).

2.3. Radiosynthesis and Quality Control of Radioligands

The radioligands used in this study, their respective targets and their affinities towards the target are summarized as follows: [¹¹¹In]In-PSMA-617 targets PSMA (K_i = 2.34 ± 2.94 nM [14]), [¹¹¹In]In-RM2 targets GRP-R (K_d = 2.9 ± 0.4 nM [15]), [¹¹¹In]In-JMV 6659 is a radioligand of NTS₁ (K_d = 6.29 ± 1.37 nM [16]), [¹¹¹In]In-JMV 7488 is a radioligand of NTS₂ (K_d = 36.39 ± 4.02 nM [17]), [¹⁷⁷Lu]Lu-DOTATATE targets SST₂ (K_d = 2.0 ± 0.8 nM [18]) and [⁶⁷Ga]Ga-pentixafor is a radioligand of CXCR4 (K_d = 24.6 ± 2.5 nM [19]). The production and control of the radiopharmaceuticals used are described in the Supplementary Materials.

2.4. High-Resolution Microimaging

2.4.1. Binding Assay

The protocol and recommendations edited by Reubi and co-workers for binding assays were strictly adhered to [20]. Frozen samples were kept at −80 °C. Three days before handling, samples were placed at −20 °C. The day of the experiment, samples were pre-incubated for 10 min at 37 °C in Tris-HCl buffer at pH 7.4. Then, a binding solution containing 10 nM of the radiopharmaceuticals (except [¹¹¹In]In-JMV 7488 and [⁶⁷Ga]Ga-pentixafor, which were used at 75 nM and 50 nM, respectively) in Tris-HCl buffer at pH 8.2, 1% of BSA (Sigma A2153), 40 µg/mL of bacitracin (Sigma®11,702), and 10 nM of MgCl₂ (Sigma M8266) was applied. In order to determine the amount of non-specific binding, a large excess of cold ligand was added—more precisely, 1 µM of [^{nat}Ga]Ga-RM2 (Life Molecular Imaging), [^{nat}Ga]Ga-PSMA-617 (ABX), neurotensin (Bachem), or [^{nat}Lu]Lu-DOTATATE (ABX), 7.5 µM of levocabastine or 10 µM pentixafor were used. Samples were incubated at 37 °C for 2 h. Afterward, samples were rinsed five times for 8 min in cold Tris-HCl buffer at pH 8.2 with 0.25% of BSA, two times for 8 min in cold Tris-HCl buffer at pH 8.2 without BSA and finally, two times for 5 min in distilled water.

2.4.2. Tissue Microimaging

A Beta Imager-2000 (Biospace Lab) device was used to image and quantify radioactivity in the samples. Acquisition duration was about 10 h (4 × 10⁶ counts).

2.5. Data Analysis

Imaging analysis was performed as previously described [7]. Briefly, HES and autoradiographic slides were fused and regions of interests (ROIs) were used to calculate

the amount of specific binding. A first ROI—drawn by the pathologist to delineate tumor areas—was applied to estimate total binding, and a second ROI—corresponding to background noise—was placed around the tissue. The same ROIs were then transferred to the adjacent slice to determine non-specific binding. After subtracting background noise, specific binding (total binding—non-specific binding) was expressed as a percentage of total binding as follows:

$$\text{Specific binding(\%)} = \frac{(\text{Total binding background}) - (\text{non specific binding background})}{\text{Total binding background}} \times 100$$

2.6. Statistical Analysis

Data, presented as the mean \pm standard deviation (SD), were compared using a non-parametric ANOVA. Statistical analyses were performed using GraphPad software (v 6.01, San Diego, CA, USA). *p* values < 0.05 were considered statistically significant.

3. Results

3.1. Study 1: Prospective NTS₁ IHC Study

Results are summarized in Table 1.

Table 1. PSMA, GRP-R and NTS₁ immunochemistry staining with IRS score according to uptake intensity (Standard Uptake Value—SUVmax) of [⁶⁸Ga]Ga-PSMA-617 and [⁶⁸Ga]Ga-RM2 Positron Emission Tomography (PET) imaging.

Patient	ISUP Score	PSMA		GRP-R		NTS ₁
		IRS	SUVmax	IRS	SUVmax	IRS
1	1	6	2.8	6	4.8	6
2	2	9	4.5	3	5.1	6
3	2	9	4.7	8	6.3	0
4	2	0	5	4	5.3	12
5	2	1	3.4	1	7.5	12
6	3	12	6.8	4	8.3	1
7	3	2	3.6	8	8.9	12
8	4	9	2.8	6	2.4	3
9	4	9	8.5	6	2.8	2
10	5	12	13.3	4	7.5	2
11	5	12	5.9	4	7.2	4
12	5	12	12.5	2	2.8	8
13	5	6	7.1	1	9.1	4
14	5	12	3.7	4	10.5	12
15	5	12	7.8	4	9	6
16	5	12	20.4	2	3.7	1

Immunochemistry was conducted on samples from prostatectomies of patients included in our previous *in vivo* study [9]. Sixteen samples were available for GRP-R, PSMA and NTS₁ staining. Staining was cytoplasmic for PSMA and GRP-R and nuclear for NTS₁ (Figure 1). GRP-R staining was considered positive (IRS \geq 4) in 11 (68.8%) of 16 lesions. The median GRP-R IRS score was 4 (3–6). PSMA IRS was considered positive (IRS \geq 4) in 15 (83.3%) of 18 lesions. The median PSMA IRS score was 11 (6–12). NTS₁ IRS was considered positive (IRS \geq 4) in 10 (62.5%) of 16 lesions. The median NTS₁ IRS score was 5 (1–12).

Interestingly, all samples with negative PSMA staining (two patients with ISUP 2 and one with ISUP 3) were strongly positive for NTS₁ staining (IRS 0 versus 12; 1 versus 12; 2 versus 12). One lesion was negative for both PSMA and GRP-R staining and strongly positive for NTS₁ staining. On the other hand, all samples with negative NTS₁ staining (*n* = 6) were positive for PSMA and five of them were positive for GRP-R. Figure 1 shows an example of a prostatic ISUP-2 sample with positive staining for NTS₁ immunochemistry

but negative staining for PSMA and GRP-R. No prostatic lesion showed negativity with all three stains for PSMA, GRP-R and NTS₁.




Figure 1. Example of a prostatic ISUP-2 sample (HES staining in (A)) negative for PSMA (B) and GRP-R (C) immunohistochemistry, but with positive staining for NTS₁ immunohistochemistry (D). Images were taken at 10× magnification.

Finally, when correlating the current NTS₁ staining results with clinical PET imaging data from patients included in the trial, four lesions were positive for NTS₁ staining with a low [⁶⁸Ga]Ga-PSMA-617 uptake (SUV_{max} < 4). One lesion was positive for NTS₁ staining with a low [⁶⁸Ga]Ga-RM2 uptake (Table 1).

3.2. Study 2: Retrospective Study of the Expression of PSMA, GRP-R, NTS₁, NTS₂, SST₂ and CXCR4 on Samples of Primary Prostate Cancer

Patient characteristics were summarized in Table 2.

3.3. Radiopharmaceuticals

[¹¹¹In]In-RM2 was used at 3.9 GBq/μmol, [¹¹¹In]In-PSMA-617 was used at 10.0 GBq/μmol, [¹¹¹In]In-JMV 6659 was used at 2.2 GBq/μmol, [¹¹¹In]In-JMV 7488 was used at 3.4 GBq/μmol, [⁶⁷Ga]Ga-pentixafor was used at 0.3 GBq/μmol and [¹⁷⁷Lu]Lu-DOTATATE was used at 14.9 GBq/μmol. All radiopharmaceuticals were produced at radiochemical purity > 95%.

Table 2. Characteristics of the patients from which samples have used in this study. ND not determined. PSA prostate specific antigen. * All patients were NxMX or NOM0 except for patient no. 31, who was stage NxM1.

Patient	Age	ISUP	Gleason Score	PSA (ng/mL)	Clinical Tumor Size: cT	Pathological Tumor Size: pT	Metastatic Risk
1	67	1	6 (3 + 3)	3.7	1	2c	High
2	65	1	6 (3 + 3)	5.26	1	2c	High
3	57	1	6 (3 + 3)	4.38	1	2a	Low
4	51	1	6 (3 + 3)	3.7	2	2a	Low
5	63	1	6 (3 + 3)	10	1	2c	High
6	48	1	6 (3 + 3)	4.51	1	2c	High
7	56	1	6 (3 + 3)	4.4	2	2c	High
8	55	1	6 (3 + 3)	3.7	2	2c	High
9	70	2	7 (3 + 4)	10.5	1	3a	High
10	67	2	7 (3 + 4)	5.65	2	2c	High
11	57	2	7 (3 + 4)	6	1	3a	High
12	66	2	7 (3 + 4)	10	2	2c	High
13	59	2	7 (3 + 4)	13	2	2b	Intermediate
14	66	2	7 (3 + 4)	14	2	2c	High
15	67	2	7 (3 + 4)	14	1	3a	High
16	66	2	7 (3 + 4)	10.4	0	3a	High
17	67	2	7 (3 + 4)	12.5	1	3a	High
18	55	2	7 (3 + 4)	13	1	3a	High
19	49	2	7 (3 + 4)	14.28	2	3b	High
20	64	3	7 (4 + 3)	8	1	3a	High
21	60	3	7 (4 + 3)	5.67	1	3b	High
22	66	3	7 (4 + 3)	4.28	2	3a	High
23	58	3	7 (4 + 3)	7.6	2	3a	High
24	71	3	7 (4 + 3)	6.4	2	3a	High
25	67	3	7 (4 + 3)	7.6	2	2c	High
26	63	3	7 (4 + 3)	28	2	nd	High
27	63	3	7 (4 + 3)	25.6	3	3b	High
28	68	3	7 (4 + 3)	19	2	3a	High
29	53	3	7 (4 + 3)	20	2	3a	High
30	75	4	8 (4 + 4)	6	3	1b	High
31 *	71	4	8 (4 + 4)	285	4	nd	High
32	63	4	8 (4 + 4)	7	2	3a	High
33	70	4	8 (4 + 4)	3.9	2	3a	High
34	70	4	8 (4 + 4)	9.95	1	2c	High
35	74	4	8 (5 + 3)	nd	nd	nd	High
36	66	4	8 (4 + 4)	44	2	3a	High
37	59	4	8 (4 + 4)	14	2	4	High
38	73	5	9 (4 + 5)	10	nd	3b	High
39	72	5	9 (4 + 5)	20	3	3b	High
40	63	5	9 (4 + 5)	27	3	3b	High
41	54	5	9 (4 + 5)	30	3	3a	High
42	60	5	9 (4 + 5)	12.6	2	3a	High
43	66	5	9 (4 + 5)	4.4	2	2a	High
44	63	5	9 (5 + 4)	5	2	3a	High
45	70	5	9 (4 + 5)	24.5	2	3b	High
46	56	5	9 (4 + 5)	26	3	3a	High

3.4. Quantitative Analysis

The specific binding (expressed as percentage over total binding) of each radiopharmaceutical according to its ISUP score is shown in Table 3.

Table 3. ISUP-based stratification and statistical analysis of samples for each target. Specific binding % \pm standard deviation (number of samples). Non-parametric one-way ANOVA (Kruskal–Wallis test). $p < 0.05$ was considered significant. * stands for significant difference.

ISUP	PSMA	GRP-R	NTS ₁	SST ₂	NTS ₂	CXCR ₄
	* < 0.0001					
1	78.8% ± 10.0 (8)	44.7% ± 51.3 (8)	38.3% ± 33.6 (6)	43.5% ± 33.0 (8)	29.4% ± 37.5 (5)	62.4% ± 21.0 (4)
	* < 0.0001					
2	81.0% ± 15.4 (11)	8.2% ± 18.3 (11)	10.0% ± 20.0 (4)	34.6% ± 28.6 (9)	37.1% ± 29.6 (7)	36.4% ± 3.1 (2)
	* < 0.0001					
3	89.0% ± 9.8 (8)	27.5% ± 29.7 (9)	64.7% ± 68.7 (6)	77.6% ± 147 (9)	36.4% ± 38.9 (9)	0% ± 0 (0)
	* < 0.0001					
4	94.7% ± 4.6 (8)	16.2% ± 27.8 (8)	39.1% ± 47.2 (7)	7.4% ± 10.0 (3)	37.3% ± 32.6 (6)	32.0% ± 45.2 (2)
	* < 0.0001					
5	73.6% ± 25.7 (8)	20.8% ± 39.4 (8)	13.3% ± 23.0 (7)	32.0% ± 28.7 (9)	54.6% ± 35.6 (6)	43.9% ± 73.3 (4)
	* < 0.0001					
Total	83.3% ± 16.0 (43)	22.5% ± 34.7 (44)	34.2% ± 44.8 (30)	43.9% ± 75.3 (38)	39.0% ± 33.8 (33)	46.8% ± 43.9 (12)

[¹¹¹In]In-PSMA-617 binding was significantly higher than [¹¹¹In]In-RM2, [¹¹¹In]In-JMV 6659, [¹¹¹In]In-JMV 7488 and [¹⁷⁷Lu]Lu-DOTATATE for all ISUP scores ($p < 0.0001$). Interestingly, no significant difference was found between [¹¹¹In]In-PSMA-617 and [⁶⁷Ga]Ga-pentixafor, but the numbers of samples that could be assessed for CXCR4 was more limited.

For each radiopharmaceutical, there was no significant difference in binding intensity between various ISUP scores.

Overall, binding of [¹¹¹In]In-PSMA-617 was high in all ISUP groups. However, it was interesting to see that some samples did not bind or bound weakly [¹¹¹In]In-PSMA-617 (9%). Therefore, a search for novel targets is needed. Below, we report the number of samples for which the binding intensity of the radiopharmaceutical was at least equal to that of [¹¹¹In]In-PSMA-617 (Table 4), six for [¹¹¹In]In-JMV 6659 (1 ISUP-1, 2 ISUP-3 and 3 ISUP-4), four for [¹¹¹In]In-JMV 7489 (1 ISUP-1, 1 ISUP-2, 1 ISUP-3 and 1 ISUP-5), three for [¹⁷⁷Lu]Lu-DOTATATE (2 ISUP-1 and 1 ISUP-3), three for [⁶⁷Ga]Ga-pentixafor (2 ISUP-1 and 1 ISUP-5) and two for [¹¹¹In]In-RM2 (1 ISUP-1 and 1 ISUP-5).

The number of samples for which the specific binding of a radiopharmaceutical was equal or higher than [¹¹¹In]In-RM2 is reported in Table 5: forty-three for PSMA (7 ISUP-1, 11 ISUP-2, 8 ISUP-3, 8 ISUP-4 and 9 ISUP-5), twenty for NTS₂ (2 ISUP-1, 5 ISUP-2, 5 ISUP-3, 5 ISUP-4 and 3 ISUP-5), nineteen for SST₂ (4 ISUP-1, 6 ISUP-2, 3 ISUP-3, 2 ISUP-4 and

4 ISUP-5) eight for NTS₁ (2 ISUP-1, 1 ISUP-2, 3 ISUP-3 and 2 ISUP-4) and eight for CXCR4 (4 ISUP-1, 2 ISUP-2 and 2 ISUP-5).

Table 4. Number of Delta \geq PSMA for GRP-R, NTS₁, SST₂, NTS₂ and CXCR₄. Note: ISUP5 NTS₂ >> PSMA (95% vs. 44%).

ISUP	GRP-R	NTS ₁	SST ₂	NTS ₂	CXCR ₄
1	1	1	2	1	2
2	0	0	0	1	0
3	0	2	1	1	0
4	0	3	0	0	0
5	1	0	0	1	1
Total	2	6	3	4	3

Table 5. Number of specific binding \geq GRPR for PSMA, NTS₁, SST₂, NTS₂ and CXCR₄.

ISUP	PSMA	NTS ₁	SST ₂	NTS ₂	CXCR ₄
1	7	2	4	2	4
2	11	1	6	5	2
3	8	3	3	5	NA
4	8	2	2	5	NA
5	9	0	4	3	2
Total	43	8	19	20	8

One ISUP-2 sample with low binding of [¹¹¹In]In-PSMA-617 and negative binding for [¹¹¹In]In-RM2 was positive only for NTS₂.

One ISUP-5 sample with negative binding of [¹¹¹In]In-PSMA-617 and [¹¹¹In]In-RM2 was positive for SST₂, NTS₂ and CXCR₄.

To illustrate these results, three different cases are presented in Figures 2–4.




Figure 2. Comparison of the binding between PSMA, GRP-R, NTS₁, NTS₂ and SST₂-specific radiopharmaceuticals on an ISUP-1 sample. The red line drawing on the HES slice corresponds to the tumor area. Specific binding = 92% for PSMA, 90% for GRP-R, 67% for NTS₁, 92% for NTS₂ and 47% for SST₂. Color scale refers to cps/mm².




Figure 3. Comparison of the binding between PSMA, GRP-R, NTS₁, NTS₂ and SST₂-specific radiopharmaceuticals on an ISUP-5 sample. The red line drawing on HES slice corresponds to the tumor area. Specific binding = 45% for PSMA, 40% for NTS₁, 95% for NTS₂ and 40% for SST₂. Specific binding was not available for GRP-R due to technical issues. Color scale refers to cps/mm².




Figure 4. Comparison between PSMA, GRP-R, NTS₁, NTS₂ and CXCR₄-specific radiopharmaceuticals on an ISUP-5 sample. The red line drawing on HES slice corresponds to the tumor area. PSMA, GRP-R and NTS₁ samples showed no uptake on the tumoral area. Contrarily, NTS₂, and CXCR₄ showed a strong tumor uptake. Specific binding = 0% for PSMA, 0% for GRP-R, 0% for NTS₁, 71% for NTS₂ and 100% for CXCR₄. Color scale refers to cps/mm².

4. Discussion

Several radiopharmaceuticals have been developed to help in the staging of prostate cancer. The radiolabeled analog of the essential amino acid leucine ¹⁸F-FACBC (¹⁸F-Flucicovine) does not demonstrate high specificity for imaging in primary prostate can-

cer [21]. Furthermore, ^{11}C -Acetate—marking lipid metabolism—cannot reliably distinguish benign prostatic hyperplasia from prostate tumors. Finally, $^{11}\text{C}/^{18}\text{F}$ -Choline—another marker of lipid metabolism—shows lower sensitivity than mpMRI for the detection of primary prostate cancer [22]. Thus, the search for novel targets appears necessary for the initial assessment of the aggressiveness of primary prostate tumors.

PSMA and GRP-R have been investigated for the initial staging of prostate cancer. In a prospective study enrolling 56 intermediate grade prostate cancer patients before prostatectomy, PSMA PET was found to be accurate in detecting intraprostatic lesions of ISUP ≥ 2 . Contrarily, the detection rate of PSMA PET was low for ISUP-1 lesions. Touijer et al. prospectively investigated ^{68}Ga]Ga-RM2 PET/CT in 16 patients before radical prostatectomy; the performance of ^{68}Ga]Ga-RM2 PET/CT imaging did not significantly differ compared to mpMRI in terms of sensitivity, specificity or accuracy [23].

Our previous study showed similar findings, as ^{68}Ga]Ga-PSMA-617 PET/CT was useful for depicting higher ISUP score lesions and ^{68}Ga]Ga-RM2 PET/CT had a higher detection rate for low-ISUP tumors [9]. In the lesion-based analysis (including lesions < 0.1 cc), ^{68}Ga]Ga-PSMA-617 PET/CT detected 74.3% of all tumor lesions and ^{68}Ga]Ga-RM2 PET/CT detected 78.1%. However, paired examinations showed negative uptake in 15.6% of lesions by both modalities. Therefore, the objective of this work was to explore new targets to detect these unseen lesions.

The prospective immunochemistry study performed in this work confirms the interest in NTS₁, as all PSMA negative lesions were strongly positive for NTS₁. Moreover, all negative NTS₁ staining lesions (37.5%) were positive for PSMA staining and positive for GRP-R staining in five patients (31%). Our results consolidate a previous study demonstrating that PSMA-negative samples from Gleason scores of 5, 6 or 7 were all NTS₁-positive [24]. Thus, the interest in NTS₁ might be greater than for GRP-R in low histological grade tumors, but comparison with GRP-R is obviously needed. Unfortunately, no NTS₁ imaging radiopharmaceutical has yet shown interesting results when applied to humans [25]. Work is ongoing to find stabilized NTS₁ analogues suitable for imaging [16,26]. These new data should also be considered with caution as IHC results do not necessarily translate into similar findings in vivo.

With this in mind, we performed a retrospective micro-imaging study comparing PSMA, GRP-R, NTS₁ as well as NTS₂, SST₂ and CXCR4 expression using specific radiopharmaceuticals that would be more representative of in vivo behavior. Overexpression of the NTS₂ receptor in prostate cancer has been reported; an in vitro study has assessed the potential use of the NTS₂ receptor as a target by analyzing its expression patterns in human prostate cell lines and primary prostate cell cultures—NTS₂ was found in cells with luminal phenotype [27]. Other studies are needed to confirm these results. SST₂ is also overexpressed in prostate cancer—especially in cases of neuroendocrine differentiation [11,28]. CXCR4 overexpression has also been reported in prostate cancer; studies have shown that CXCR4 is a key regulator of tumor dissemination [12]. An in vitro study comparing adjacent normal endothelial cells to prostate tumor vasculature highlighted CXCR4 as a potential novel target to interfere with prostate cancer angiogenesis [29].

While our work shows the superiority of PSMA for the detection of intraprostatic lesions, with a significant higher binding of ^{111}In]In-PSMA-617 than ^{111}In]In-RM2, ^{111}In]In-JMV 6659, ^{177}Lu]Lu-DOTATATE or ^{111}In]In-JMV 7488 for all ISUP-score groups (no significant difference was found for CXCR4—mostly due to a lack of power), and PSMA PET has now entered into guidelines [30], alternative targets are necessary in the event of PSMA negativity. In a previous study enrolling fifty newly diagnosed patient with prostate cancer, the ^{68}Ga]Ga-PSMA-617 PET/CT was negative in 12.5% [31]. Targeting the GRP-R is expected to cover the limitations of PSMA [9]. In our work, in ISUP scores 1, binding of ^{111}In]In-RM2, ^{111}In]In-JMV 6659 and ^{111}In]In-JMV 7488 were higher than that of ^{111}In]In-PSMA-617 in one case (the same case for ^{111}In]In-RM2 and ^{111}In]In-JMV 7488, a different one for ^{111}In]In-JMV 6659). In the ISUP-2 group, only ^{111}In]In-JMV 7488 showed a higher signal than ^{111}In]In-PSMA-617. In the ISUP 3 group, two samples

showed higher [^{111}In]In-JMV 6659 binding than [^{111}In]In-PSMA-617—one sample showed higher binding of [^{177}Lu]Lu-DOTATATE than [^{111}In]In-PSMA-617 and another sample also showed higher binding of [^{111}In]In-JMV 7488 than [^{111}In]In-PSMA-617. Indeed, no statistical analyses were performed due to the low number of samples.

Overall, the most interesting targets to cover PSMA-negative lesions appear to be NTS₁ and NTS₂—with, respectively, four and six cases with superior or equivalent detection than PSMA, covering all ISUP scores. It is interesting to note that combining PSMA and NTS₁/NTS₂ could allow for the detection of all intraprostatic lesions. The new findings in this work also highlight the potential of multireceptor-targeting radioprobes that can still bind one target (NTS₁ or NTS₂ or GRP-R) when the other is lost (PSMA). Works are ongoing to optimize radiolabeled PSMA/GRP-R heterobivalent probes [32], while the development of PSMA/NTS₁ heterodimers has only been described once [33]. Overall, this work sheds light on the abundance of different neuropeptide receptors (mainly neurotensin receptors) in different physiopathological states of prostate cancer.

The improved detection of lesions allows for better mapping of prostate tumor pathology, which is necessary for biopsy guiding to decrease the discordance rate of staging of biopsies and final staging of prostatectomy samples. Finally, the possibility of a more precise detection and characterization of intra-prostatic lesions opens new avenues for radiotherapy planning and/or focal treatments.

The reader should be aware that it was not our aim to compare radiopharmaceuticals, but rather to use them to quantify receptor density in primary prostate cancer samples. Moreover, in this work, we were not able to provide the uptake (as a percentage of the applied dose) of each radiopharmaceutical.

5. Conclusions

In this work, we have compared GRP-R, PSMA, NTS₁, NTS₂, SST₂ and CXCR4 expression in vitro in primary prostate cancer samples. Our results confirm that PSMA remains the best target in tumor detection at initial staging—especially for high grade lesions. Interestingly, targeting NTS₁ and NTS₂ allowed us to detect all PSMA-negative lesions more precisely than GRP-R in vitro. Future in vivo prospective studies must confirm these data.

Supplementary Materials: The following supporting information can be downloaded at: <https://www.mdpi.com/article/10.3390/cancers15082345/s1>, Procedure for the preparation and quality control of the radiopharmaceuticals.

Author Contributions: Conceptualization, H.d.C.G., E.H. and C.M.; Methodology, M.-L.Q.R. and C.M.; Formal Analysis, R.S.; Resources, D.V., F.C., I.E.V. and R.S.; Writing—Original Draft Preparation, R.S.; Writing—Review and Editing, E.H., F.C., I.E.V. and C.M.; Supervision, C.M.; Funding Acquisition, R.S. All authors have read and agreed to the published version of the manuscript.

Funding: This work received funding from INCa—canceropole GSO (grant number 2020-E19) and financial support from ITMO Cancer of Aviesan within the framework of the 2021–2023 Cancer Control Strategy; funds administered by Inserm (grant number 22CP154-00).

Institutional Review Board Statement: Patient samples were obtained with informed consent in accordance with the Declaration of Helsinki and stored at the “CRB Cancer des Hôpitaux de Toulouse (BB-0033-00014)” collection. According to French law, the CRB Cancer collection was declared to the Ministry of Higher Education and Research (DC-2008-463) and a transfer agreement was obtained (AC-2013-1955) after approval by ethical committees (Conseil Scientifique du Centre de Ressources Biologiques).

Informed Consent Statement: Informed consent was obtained from all subjects involved in this study.

Data Availability Statement: The data presented in this study are available on request from the corresponding author. The data are not publicly available due to privacy.

Acknowledgments: This study was conducted in the framework of the University of Bordeaux IdEx “Investments for the Future” program RRI “NewMOON”, which received financial support from the French Government.

Conflicts of Interest: Life Molecular Imaging provided the RM2 precursor and the [^{nat}Ga]Ga-RM2 reference compound, but had no role in the design, execution, interpretation, or writing of the study. The authors declare no other conflict of interest.

References

1. Siegel, R.L.; Miller, K.D.; Wagle, N.S.; Jemal, A. Cancer statistics, 2023. *CA Cancer J. Clin.* **2023**, *73*, 17–48. [[CrossRef](#)] [[PubMed](#)]
2. Fütterer, J.J.; Briganti, A.; De Visschere, P.; Emberton, M.; Giannarini, G.; Kirkham, A.; Taneja, S.S.; Thoeny, H.; Villeirs, G.; Villers, A. Can Clinically Significant Prostate Cancer Be Detected with Multiparametric Magnetic Resonance Imaging? A Systematic Review of the Literature. *Eur. Urol.* **2015**, *68*, 1045–1053. [[CrossRef](#)] [[PubMed](#)]
3. Grenabo Bergdahl, A.; Wilderäng, U.; Aus, G.; Carlsson, S.; Damber, J.-E.; Franlund, M.; Geterud, K.; Khatami, A.; Socratous, A.; Stranne, J.; et al. Role of Magnetic Resonance Imaging in Prostate Cancer Screening: A Pilot Study Within the Göteborg Randomised Screening Trial. *Eur. Urol.* **2016**, *70*, 566–573. [[CrossRef](#)] [[PubMed](#)]
4. Siddiqui, M.M.; Rais-Bahrami, S.; Turkbey, B.; George, A.K.; Rothwax, J.; Shakir, N.; Okoro, C.; Raskolnikov, D.; Parnes, H.L.; Linehan, W.M.; et al. Comparison of MR/Ultrasound Fusion-Guided Biopsy With Ultrasound-Guided Biopsy for the Diagnosis of Prostate Cancer. *JAMA* **2015**, *313*, 390. [[CrossRef](#)]
5. Maurer, T.; Eiber, M.; Schwaiger, M.; Gschwend, J.E. Current use of PSMA-PET in prostate cancer management. *Nat. Rev. Urol.* **2016**, *13*, 226–235. [[CrossRef](#)]
6. Hofman, M.S.; Lawrentschuk, N.; Francis, R.J.; Tang, C.; Vela, I.; Thomas, P.; Rutherford, N.; Martin, J.M.; Frydenberg, M.; Shaker, R.; et al. Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): A prospective, randomised, multicentre study. *Lancet* **2020**, *395*, 1208–1216. [[CrossRef](#)]
7. Morgat, C.; Schollhammer, R.; MacGrogan, G.; Barthe, N.; Vélasco, V.; Vimont, D.; Cazeau, A.-L.; Fernandez, P.; Hindié, E. Comparison of the binding of the gastrin-releasing peptide receptor (GRP-R) antagonist ⁶⁸Ga-RM2 and ¹⁸F-FDG in breast cancer samples. *PLoS ONE* **2019**, *14*, e0210905. [[CrossRef](#)]
8. Schollhammer, R.; Gallerande, H.D.C.; Yacoub, M.; Ranty, M.-L.Q.; Barthe, N.; Vimont, D.; Hindié, E.; Fernandez, P.; Morgat, C. Comparison of the radiolabeled PSMA-inhibitor ¹¹¹In-PSMA-617 and the radiolabeled GRP-R antagonist ¹¹¹In-RM2 in primary prostate cancer samples. *EJNMMI Res.* **2019**, *9*, 52. [[CrossRef](#)]
9. Schollhammer, R.; Robert, G.; Asselineau, J.; Yacoub, M.; Vimont, D.; Balamoutoff, N.; Bladou, F.; Bénard, A.; Hindié, E.; de Clermont Gallerande, E.; et al. Comparison of ⁶⁸Ga-PSMA-617 PET/CT and ⁶⁸Ga-RM2 PET/CT in patients with localized prostate cancer candidate for radical prostatectomy: A prospective, single arm, single center, phase II study. *J. Nucl. Med.* **2023**, *64*, 379–385. [[CrossRef](#)]
10. Morgat, C.; Chastel, A.; Molinie, V.; Schollhammer, R.; Macgrogan, G.; Vélasco, V.; Malavaud, B.; Fernandez, P.; Hindié, E. Neurotensin Receptor-1 Expression in Human Prostate Cancer: A Pilot Study on Primary Tumors and Lymph Node Metastases. *Int. J. Mol. Sci.* **2019**, *20*, 1721. [[CrossRef](#)]
11. Morichetti, D.; Mazzucchelli, R.; Santinelli, A.; Stramazotti, D.; Lopez-Beltran, A.; Scarpelli, M.; Bono, A.; Cheng, L.; Montironi, R. Immunohistochemical Expression and Localization of Somatostatin Receptor Subtypes in Prostate Cancer with Neuroendocrine Differentiation. *Int. J. Immunopathol. Pharmacol.* **2010**, *23*, 511–522. [[CrossRef](#)] [[PubMed](#)]
12. Dubrovskaya, A.; Elliott, J.; Salamone, R.J.; Telegeev, G.D.; Stakhovskiy, A.E.; Schepotin, I.B.; Yan, F.; Wang, Y.; Bouchez, L.C.; Kularatne, S.A.; et al. CXCR4 Expression in Prostate Cancer Progenitor Cells. *PLoS ONE* **2012**, *7*, e31226. [[CrossRef](#)] [[PubMed](#)]
13. Morgat, C.; Bonnefoi, H.; MacGrogan, G.; Brouste, V.; Vélasco, V.; Sévenet, N.; Fernandez, P.; Debled, M.; Hindié, E. Expression of Gastrin-Releasing Peptide Receptor in Breast Cancer and Its Association with Pathologic, Biologic, and Clinical Parameters: A Study of 1,432 Primary Tumors. *J. Nucl. Med.* **2017**, *58*, 1401–1407. [[CrossRef](#)] [[PubMed](#)]
14. Benešová, M.; Schäfer, M.; Bauder-Wüst, U.; Afshar-Oromieh, A.; Kratochwil, C.; Mier, W.; Haberkorn, U.; Kopka, K.; Eder, M. Preclinical Evaluation of a Tailor-Made DOTA-Conjugated PSMA Inhibitor with Optimized Linker Moiety for Imaging and Endoradiotherapy of Prostate Cancer. *J. Nucl. Med.* **2015**, *56*, 914–920. [[CrossRef](#)]
15. Chastel, A.; Vimont, D.; Claverol, S.; Zerna, M.; Bodin, S.; Berndt, M.; Chaignepain, S.; Hindié, E.; Morgat, C. ⁶⁸Ga-Radiolabeling and Pharmacological Characterization of a Kit-Based Formulation of the Gastrin-Releasing Peptide Receptor (GRP-R) Antagonist RM2 for Convenient Preparation of [⁶⁸Ga]Ga-RM2. *Pharmaceutics* **2021**, *13*, 1160. [[CrossRef](#)]
16. Fanelli, R.; Chastel, A.; Previti, S.; Hindié, E.; Vimont, D.; Zanotti-Fregonara, P.; Fernandez, P.; Garrigue, P.; Lamare, F.; Schollhammer, R.; et al. Silicon-Containing Neurotensin Analogues as Radiopharmaceuticals for NTS₁-Positive Tumors Imaging. *Bioconjug. Chem.* **2020**, *31*, 2339–2349. [[CrossRef](#)]
17. Bodin, S.; Previti, S.; Jestin, E.; Vimont, D.; Ait-Arsa, I.; Lamare, F.; Rémond, E.; Hindié, E.; Cavelier, F.; Morgat, C. Design, Synthesis, and Biological Evaluation of the First Radio-Metalated Neurotensin Analogue Targeting Neurotensin Receptor 2. *ACS Omega* **2023**, *8*, 6994–7004. [[CrossRef](#)]
18. Schottelius, M.; Šimeček, J.; Hoffmann, F.; Willibald, M.; Schwaiger, M.; Wester, H.-J. Twins in spirit—episode I: Comparative preclinical evaluation of [⁶⁸Ga]DOTATATE and [⁶⁸Ga]HA-DOTATATE. *EJNMMI Res.* **2015**, *5*, 22. [[CrossRef](#)]
19. Poschenrieder, A.; Schottelius, M.; Schwaiger, M.; Kessler, H.; Wester, H.-J. The influence of different metal-chelate conjugates of pentixafor on the CXCR4 affinity. *EJNMMI Res.* **2016**, *6*, 36. [[CrossRef](#)]

20. Reubi, J.C.; Kvols, L.K.; Waser, B.; Nagorney, D.M.; Heitz, P.U.; Charboneau, J.W.; Reading, C.C.; Moertel, C. Detection of somatostatin receptors in surgical and percutaneous needle biopsy samples of carcinoids and islet cell carcinomas. *Cancer Res.* **1990**, *50*, 5969–5977.
21. Parent, E.E.; Schuster, D.M. Update on ¹⁸F-Fluciclovine PET for Prostate Cancer Imaging. *J. Nucl. Med.* **2018**, *59*, 733–739. [[CrossRef](#)] [[PubMed](#)]
22. Nitsch, S.; Hakenberg, O.W.; Heuschkel, M.; Dräger, D.; Hildebrandt, G.; Krause, B.J.; Schwarzenböck, S.M. Evaluation of Prostate Cancer with ¹¹C- and ¹⁸F-Choline PET/CT: Diagnosis and Initial Staging. *J. Nucl. Med.* **2016**, *57*, 38S–42S. [[CrossRef](#)] [[PubMed](#)]
23. Touijer, K.A.; Michaud, L.; Alvarez, H.A.V.; Gopalan, A.; Kossatz, G.M.; Gonen, M.; Beattie, B.; Sandler, I.; Lyaschenko, S.; Eastham, J.A.; et al. Prospective Study of the Radiolabeled GRPR Antagonist BAY86-7548 for Positron Emission Tomography/Computed Tomography Imaging of Newly Diagnosed Prostate Cancer. *Eur. Urol. Oncol.* **2019**, *2*, 166–173. [[CrossRef](#)]
24. He, T.; Wang, M.; Wang, H.; Tan, H.; Tang, Y.; Smith, E.; Wu, Z.; Liao, W.; Hu, S.; Li, Z. Evaluation of neurotensin receptor 1 as potential biomarker for prostate cancer theranostic use. *Eur. J. Nucl. Med. Mol. Imaging* **2019**, *46*, 2199–2207. [[CrossRef](#)]
25. Prignon, A.; Provost, C.; Alshoukr, F.; Wendum, D.; Couvelard, A.; Barbet, J.; Forgez, P.; Talbot, J.-N.; Gruaz-Guyon, A. Preclinical Evaluation of ⁶⁸Ga-DOTA-NT-20.3: A Promising PET Imaging Probe To Discriminate Human Pancreatic Ductal Adenocarcinoma from Pancreatitis. *Mol. Pharm.* **2019**, *16*, 2776–2784. [[CrossRef](#)]
26. Maschauer, S.; Greff, C.; Einsiedel, J.; Ott, J.; Tripal, P.; Hübner, H.; Gmeiner, P.; Prante, O. Improved radiosynthesis and preliminary in vivo evaluation of a ¹⁸F-labeled glycopeptide-peptoid hybrid for PET imaging of neurotensin receptor 2. *Bioorg. Med. Chem.* **2015**, *23*, 4026–4033. [[CrossRef](#)] [[PubMed](#)]
27. Swift, S.L.; Burns, J.E.; Maitland, N.J. Altered Expression of Neurotensin Receptors Is Associated with the Differentiation State of Prostate Cancer. *Cancer Res.* **2010**, *70*, 347–356. [[CrossRef](#)] [[PubMed](#)]
28. Reubi, J.C.; Waser, B.; Mäcke, H.; Rivier, J.E. Highly Increased ¹²⁵I-JR11 Antagonist Binding In Vitro Reveals Novel Indications for sst₂ Targeting in Human Cancers. *J. Nucl. Med.* **2017**, *58*, 300–306. [[CrossRef](#)]
29. Heidegger, I.; Fotakis, G.; Offermann, A.; Goveia, J.; Daum, S.; Salcher, S.; Noureen, A.; Timmer-Boscha, H.; Schäfer, G.; Walenkamp, A.; et al. Comprehensive characterization of the prostate tumor microenvironment identifies CXCR4/CXCL12 crosstalk as a novel antiangiogenic therapeutic target in prostate cancer. *Mol. Cancer.* **2022**, *21*, 132. [[CrossRef](#)]
30. Available online: <https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1459> (accessed on 16 February 2023).
31. Liu, C.; Liu, T.; Zhang, N.; Liu, Y.; Li, N.; Du, P.; Yang, Y.; Liu, M.; Gong, K.; Yang, X.; et al. ⁶⁸Ga-PSMA-617 PET/CT: A promising new technique for predicting risk stratification and metastatic risk of prostate cancer patients. *Eur. J. Nucl. Med. Mol. Imaging* **2018**, *45*, 1852–1861. [[CrossRef](#)]
32. Judmann, B.; Braun, D.; Wängler, B.; Schirmacher, R.; Fricker, G.; Wängler, C. Current state of radiolabeled heterobivalent peptidic ligands in tumor imaging and therapy. *Pharmaceuticals* **2020**, *13*, 173. [[CrossRef](#)] [[PubMed](#)]
33. Ma, X.; Wang, M.; Wang, H.; Zhang, T.; Wu, Z.; Sutton, M.V.; Popik, V.V.; Jiang, G.; Li, Z. Development of bispecific NT-PSMA heterodimer for prostate cancer imaging: A potential approach to address tumor heterogeneity. *Bioconjug. Chem.* **2019**, *30*, 1314–1322. [[CrossRef](#)] [[PubMed](#)]

Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.